首页  > 师资队伍  ->硕士导师

潘雄飞

作者: 何艳平   发布时间:2022-06-15 15:16  阅读人数:

潘雄飞,四川大学华西第二医院研究员、华西第二医院西部妇幼医学研究院流行病学与人群健康实验室负责人(PI)、金沙2004线路检测硕士研究生导师。曾先后在英国伦敦卫生与热带病学院(硕士)、四川大学华西金沙2004线路检测(博士)、华中科技大学同济医学院金沙2004线路检测(博士后)、澳大利亚乔治全球健康研究院(博士后)、美国范德堡大学医学中心(博士后)接受严格的流行病学、生物统计学、公共卫生、营养学相关教育和科研培训,长期致力于基于大型纵向队列探索心血管代谢性疾病的危险因素、病因机制、不良健康影响。流行病学与人群健康实验室主要在如下三个方向开展研究工作:1)心血管代谢性疾病系统流行病学研究;2)疾病生命早期起源和全生命周期流行病学研究;3)健康相关复杂表型的队列研究/队列联盟研究。已累计在Lancet Diabetes & Endocrinology(2篇封面文章)、Diabetologia、American Journal of Clinical Nutrition(2篇)、European Journal of Endocrinology、Environment International、The Journals of Gerontology: Series A Medical Sciences、Engineering、Journal of Clinical Endocrinology and Metabolism(3篇)、American Journal of Epidemiology、Obesity(2篇)等著名学术期刊上发表40余篇第一作者或通讯作者(含共同)学术文章。实验室已建立流行病学、生物统计学、生物信息学、营养学、微生物组学跨学科研究团队。

Email:pxiongfei@scu.edu.cn

ResearchGate页面:https://www.researchgate.net/profile/Xiongfei-Pan

部分代表性论文介绍:

  1. Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol. 2021; 9(6):373-392

  2. Zeng Q#, Li N#,Pan XF#, Chen L, Pan A. Clinical management and treatment of obesity in China. Lancet Diabetes Endocrinol. 2021; 9(6): 373-92 (#共同第一作者)

  3. Pan XF#, Yang JJ#, Shu XO, Moore SC, Palmer ND, Guasch-Ferré M, Herrington DM, Harada S, Eliassen H, Wang TJ, Gerszten RE, Albanes D, Tzoulaki I, Karaman I, Elliott P, Zhu H, Wagenknecht LE, Zheng W, Cai H, Cai Q, Matthews CE, Menni C, Meyer KA, Lipworth LP, Ose J, Fornage M, Ulrich C, Yu D. Associations of circulating choline and its related metabolites with cardiometabolic biomarkers: an international pooled analysis. Am J Clin Nutr. 2021; 114(3): 893-906 (#共同第一作者)

  4. Pan XF#, Huang Y#, Li X#, Wang Y, Ye Y, Chen H, Marklund M, Wen Y, Liu Y, Zeng H, Qi X, Yang X, Yang CX, Liu G, Gibson RA, Xu S, Yu D, Chen D, Li Y, Mei ZX, Pan A, Wu JHY. Circulating fatty acids and risk of gestational diabetes mellitus: prospective analyses in China. Eur J Endocrinol. 2021; 185(1): 87-97 (#共同第一作者)

  5. Pan XF, Xu J, Meng Q.Integrating social health insurance systems in China. Lancet. 2016; 387 (10025): 1274–75(correspondence)

  6. Pan XF, Li RL, Pan A, Heidi L. Human papillomavirus vaccine approval in China: a major step forward but challenges ahead. Lancet Infect Dis. 2016; 16 (2):1322–1323 (comment)

  7. Pan XF, Li Y, Franco OH, Yuan JM, Pan A, Koh WP. Impact of combined lifestyle factors on all-cause and cause-specific mortality and life expectancy in Chinese: the Singapore Chinese Health Study. J Gerontol A Biol Sci Med Sci. 2020; 75 (11), 2193-2199

  8. Pan XF, He MA, Yu CQ, Lv J, Guo Y, Bian Z, Yang L, Chen YP, Wu TC, Chen ZM, Pan A, Li LM. Type 2 diabetes and risk of incident cancer in China: a prospective study among 0.5 million Chinese adults. Am J Epidemiol. 2018;187 (7): 1380-1391

  9. Wang Y, Huang Y, Wu P, Ye Y, Sun F, Yang X, Lu Q, Yuan J, Liu Y, Zeng H, Song X, Yan S, Qi X, Yang CX, Lv G, Wu JHY, Liu G,Pan XF*, Chen D, Pan A*. Plasma lipidomics in early pregnancy and risk of gestational diabetes mellitus: a prospective nested case-control study in Chinese women. Am J Clin Nutr 2021;114(5):1763-1773(*共同通讯)

  10. Pan XF,Yang J, Wen Y, Li N, Chen S, Pan A. Non-communicable diseases during the COVID-19 pandemic and beyond. Engineering. 2021; 7(7): 899–902.

Baidu
sogou